Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Market Exclusive Research Weekly Biotech Report

NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.

This weeks report covers the following companies:

- Clovis Oncology Inc (NASDAQ: CLVS)
- Chiasma Inc (NASDAQ: CHMA)
- Sarepta Therapeutics Inc (NASDAQ: SRPT)
- Collegium Pharmaceutical Inc. (NASDAQ: COLL)
- Progenics Pharmaceuticals (Nasdaq: PGNX)

Click here to continue reading.

SOURCE: Market Exclusive



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today